Safety and Tolerability of Neoadjuvant Radiotherapy Combined With Anti-PD-1 Antibody Toripalimab for Locally Advanced, Resectable Esophageal Squamous Cell Cancer: A Prospective Phase IB Trial

被引：0
|
作者：
Sun, H. [1 ]
Yang, W. [1 ]
Luo, J. [1 ]
Lin, H. [1 ]
Zhou, T. [2 ]
Gong, H. [3 ]
Zhao, D. [1 ]
Niu, Z. [1 ]
Liu, B. [1 ]
Wang, Z. [4 ]
Li, B. [1 ]
机构：
[1] Shandong First Med Univ & Shandong Acad Med Sci, Shandong Canc Hosp & Inst, Jinan, Peoples R China
[2] Shandong Canc Hosp, Dept Radiat Oncol, Jinan, Shandong, Peoples R China
[3] Shandong Canc Hosp & Inst, Jinan, Shandong, Peoples R China
[4] Shandong Canc Hosp, Jinan, Peoples R China
来源：
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2021年 / 111卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1014
引用
收藏
页码：S102 / S103
页数：2
相关论文
共 50 条
  • [41] Neoadjuvant toripalimab combined with gemcitabine and cisplatin in resectable locally advanced head and neck squamous cell carcinoma (NeoTGP01): An open-label, single-arm, phase Ib clinical trial.
    Liu, Zhigang
    Huang, Xiaotao
    Liang, Jun
    Zhong, Guihua
    Liu, Ye
    Liang, Lizhong
    Hong, Haiyu
    Feng, Weineng
    Yang, Shuang
    Zhang, Yaqin
    Peng, Yingpeng
    Liu, Qiandan
    Zhou, Yuling
    Zhang, Zhaoyuan
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [42] Tislelizumab combined with neoadjuvant chemoradiotherapy for resectable locally advanced oesophageal squamous cell carcinoma: A prospective, phase II clinical study
    Zhang, Y.
    Yuan, Y.
    Xu, Y.
    Tian, R.
    Liao, J.
    Zeng, X.
    Wang, Y.
    Liu, Y.
    Zhou, X.
    Peng, F.
    Zhou, L.
    Wang, H.
    Hou, W.
    Yu, M.
    Xiu, W.
    Huang, M.
    Zhang, X.
    Gong, Y.
    Lu, Y.
    Zou, B.
    ANNALS OF ONCOLOGY, 2023, 34 : S865 - S865
  • [43] A pilot study of neoadjuvant combination of anti-PD-1 camrelizumab and VEGFR2 inhibitor apatinib for locally advanced resectable oral squamous cell carcinoma
    Ju, Wu-tong
    Xia, Rong-hui
    Zhu, Dong-wang
    Dou, Sheng-jin
    Zhu, Guo-pei
    Dong, Min-jun
    Wang, Li-zhen
    Sun, Qi
    Zhao, Tong-chao
    Zhou, Zhi-hang
    Liang, Si-yuan
    Huang, Ying-ying
    Tang, Yong
    Wu, Si-cheng
    Xia, Jing
    Chen, Shi-qing
    Bai, Yue-zong
    Li, Jiang
    Zhu, Qi
    Zhong, Lai-ping
    NATURE COMMUNICATIONS, 2022, 13 (01)
  • [44] A pilot study of neoadjuvant combination of anti-PD-1 camrelizumab and VEGFR2 inhibitor apatinib for locally advanced resectable oral squamous cell carcinoma
    Wu-tong Ju
    Rong-hui Xia
    Dong-wang Zhu
    Sheng-jin Dou
    Guo-pei Zhu
    Min-jun Dong
    Li-zhen Wang
    Qi Sun
    Tong-chao Zhao
    Zhi-hang Zhou
    Si-yuan Liang
    Ying-ying Huang
    Yong Tang
    Si-cheng Wu
    Jing Xia
    Shi-qing Chen
    Yue-zong Bai
    Jiang Li
    Qi Zhu
    Lai-ping Zhong
    Nature Communications, 13
  • [45] Cisplatin plus anti-PD-1 antibody enhanced treatment efficacy in advanced esophageal squamous cell carcinoma
    Lin, Wu
    Qian, Jiong
    Wang, Haohao
    Ren, Ling
    Yang, Yan
    Chen, Chuanzhi
    Chen, Xiangliu
    Huang, Yingying
    Liu, Jin
    Xu, Nong
    Teng, Lisong
    AMERICAN JOURNAL OF CANCER RESEARCH, 2022, 12 (02): : 451 - +
  • [46] Three courses of neoadjuvant camrelizumab combined with chemotherapy in locally advanced esophageal squamous cell carcinoma (ESCC): A prospective phase II clinical trial
    Yang, G.
    Sun, X.
    Yang, H.
    Luo, G.
    Zheng, Y.
    Huang, M.
    Wang, Z.
    Cai, P.
    He, H.
    Xiang, J.
    Cai, M.
    Fu, J.
    Liu, Q.
    Yi, H.
    Zhong, J.
    Huang, Y.
    Guo, Q.
    Zhang, X.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1122 - S1122
  • [47] Neoadjuvant combined anti-PD-1 and anti-CTLA-4 inhibitor therapy for locally-advanced resectable head and neck squamous cell carcinoma: systematic review and meta-analysis
    Shin, Donghoon
    Park, Robin
    Lee, Sunggon
    Lee, Woo Joo
    Yu, James
    Shahzad, Moazzam
    Rabinowits, Guilherme
    CANCER IMMUNOLOGY RESEARCH, 2025, 13 (02)
  • [48] Radiotherapy for patients with locally advanced esophageal squamous cell carcinoma receiving neoadjuvant immunotherapy combined with chemotherapy
    Kong, Yue
    Su, Miaoyi
    Fang, Jun
    Chen, Mengyuan
    Zheng, Chao
    Jiang, Youhua
    Tao, Kaiyi
    Wang, Changchun
    Qiu, Guoqin
    Ji, Yongling
    Wang, Yuezhen
    Yang, Yang
    SCIENTIFIC REPORTS, 2024, 14 (01):
  • [49] Neoadjuvant tislelizumab combined with chemoradiotherapy for resectable locally advanced esophageal squamous cell carcinoma (ESCC): Single arm phase II study
    Jin, Peng
    Gao, Yong Sheng
    Fu, Zheng
    Yang, Wen Feng
    Meng, Xue
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [50] Radiotherapy for Patients with Locally Advanced Esophageal Squamous Cell Carcinoma Receiving Neoadjuvant Immunotherapy Combined with Chemotherapy
    Kong, Y.
    Ji, Y.
    Qiu, G.
    Wang, Y.
    Fang, J.
    Chen, M.
    Chen, Q.
    Jiang, Y.
    Yang, Y.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2023, 117 (02): : E309 - E310
12345